

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 64989

**Title:** HE Negative by IHC(1+) but Positive by FISH after Neoadjuvant Chemotherapy in Invasive Breast Cancer: A Case Report and Review

**Reviewer's code:** 05830723

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-28

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-05-02 22:50

**Reviewer performed review:** 2021-05-15 17:59

**Review time:** 12 Days and 19 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors reported a case showing the disparity on IHC and FISH testing results on HER2 post neoadjuvant chemotherapy. The manuscript is well-written and easy to understand. Specific comments are: (1) The authors mentioned that only ~2% of the patients show the discrepancy on HER2 IHC and FISH testing which referred to a study by Shui R et al. Although the sample size is 12,467, it mainly represents one ethnicity. How about this phenomenon (discrepancy on IHC and FISH) in other populations around the world? (2) Luminal A breast cancer is ER and/or PR positive , HER2 negative and low Ki-67 level. Is Ki-67 level tested along with ER, PR and HER2 pre- and post-NACT? (3) The magnification of FISH figures should be indicated in the figure legend. It is preferred to use arrows to point out positive foci representing HER2 amplification. (4) Is lumpectomy a better medical term to describe "breast-conserving surgery"? (5) Is there any follow-up testing for this case? What's your opinions on the possible, post-NACT changes of the HER2 signature over time?